Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral ...

Orforglipron, a once-daily pill, has outperformed oral semaglutide in a phase 3 clinical trial, showing greater efficacy in managing blood sugar levels and promoting weight loss.

The Matrix 5 finally gets a promising update 5 years after the last film in the franchise hit theaters. See what ...

Significant blood pressure, heart rate effects shown in placebo-controlled trial ...

A once-daily experimental GLP-1 pill shows greater weight loss and blood sugar control than current oral options, and could soon reshape obesity and diabetes care.

It looks like Apple isn’t the only company with new products launching soon. A new Sonos Play portable Bluetooth ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Trump’s proposed ACA plans carry sky-high deductibles; Rare disease advocates fume over the FDA’s mixed signals; Cardiovascular disease on the rise among young women.

Presidents' Day is over, but some deals are still available like the Samsung Galaxy Book 4 laptop for $281 off and a 23% ...

A server gets 90 seconds to deliver two soggy bread slices, three waters at boiling, room temp, and ice-cold, plus lemon ...

Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year. Learn why NVO stock is a strong buy.